Dual GIP/GLP-1 receptor agonists , like tirzepatide, take this one step further
R.AnithK
The starting dose of Wegovy for all patients is 0.25 mg once weekly
The pills haven't been compared head-to-head in a clinical trial, but in separate studies, the Wegovy pill showed average weight loss of 14% over 64 weeks, compared with 2% for a placebo, while orforglipron showed 11% weight loss over 72 weeks on its highest dose, compared with 2% for the placebo group
Laws, Evaluation of potential sodium-iodide symporter (NIS) inhibitors using a secondary Fischer rat thyroid follicular cell (FRTL-5) radioactive iodide uptake (RAIU) assay
When your doctor asks why you want a GLP-1, you should be able to explain that these medications address the neurohormonal pathways that regulate appetite and energy balance